Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Apr 24;4(4):CD008581.
doi: 10.1002/14651858.CD008581.pub2.

Antidepressants for the treatment of people with co-occurring depression and alcohol dependence

Roberta Agabio  1 , Emanuela Trogu, Pier Paolo Pani
Affiliations
Meta-Analysis

Antidepressants for the treatment of people with co-occurring depression and alcohol dependence

Roberta Agabio et al. Cochrane Database Syst Rev. .

Abstract

Background: Alcohol dependence is a major public health problem characterized by recidivism, and medical and psychosocial complications. The co-occurrence of major depression in people entering treatment for alcohol dependence is common, and represents a risk factor for morbidity and mortality, which negatively influences treatment outcomes.

Objectives: To assess the benefits and risks of antidepressants for the treatment of people with co-occurring depression and alcohol dependence.

Search methods: We searched the Cochrane Drugs and Alcohol Group Specialised Register (via CRSLive), Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase from inception to July 2017. We also searched for ongoing and unpublished studies via ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (apps.who.int/trialsearch/).All searches included non-English language literature. We handsearched references of topic-related systematic reviews and the included studies.

Selection criteria: Randomized controlled trials and controlled clinical trials comparing antidepressants alone or in association with other drugs or psychosocial interventions (or both) versus placebo, no treatment, and other pharmacological or psychosocial interventions.

Data collection and analysis: We used standard methodological procedures as expected by Cochrane.

Main results: We included 33 studies in the review (2242 participants). Antidepressants were compared to placebo (22 studies), psychotherapy (two studies), other medications (four studies), or other antidepressants (five studies). The mean duration of the trials was 9.9 weeks (range 3 to 26 weeks). Eighteen studies took place in the USA, 12 in Europe, two in Turkey, and one in Australia. The antidepressant included in most of the trials was sertraline; other medications were amitriptyline, citalopram, desipramine, doxepin, escitalopram, fluoxetine, fluvoxamine, imipramine, mianserin, mirtazepine, nefazodone, paroxetine, tianeptine, venlafaxine, and viloxazine. Eighteen studies were conducted in an outpatient setting, nine in an inpatient setting, and six in both settings. Psychosocial treatment was provided in 18 studies. There was high heterogeneity in the selection of outcomes and the rating systems used for diagnosis and outcome assessment.Comparing antidepressants to placebo, low-quality evidence suggested that antidepressants reduced the severity of depression evaluated with interviewer-rated scales at the end of trial (14 studies, 1074 participants, standardized mean difference (SMD) -0.27, 95% confidence interval (CI) -0.49 to -0.04). However, the difference became non-significant after the exclusion of studies with a high risk of bias (SMD -0.17, 95% CI -0.39 to 0.04). In addition, very low-quality evidence supported the efficacy of antidepressants in increasing the response to the treatment (10 studies, 805 participants, risk ratio (RR) 1.40, 95% Cl 1.08 to 1.82). This result became non-significant after the exclusion of studies at high risk of bias (RR 1.27, 95% CI 0.96 to 1.68). There was no difference for other relevant outcomes such as the difference between baseline and final score, evaluated using interviewer-rated scales (5 studies, 447 participants, SMD 0.15, 95% CI -0.12 to 0.42).Moderate-quality evidence found that antidepressants increased the number of participants abstinent from alcohol during the trial (7 studies, 424 participants, RR 1.71, 95% Cl 1.22 to 2.39) and reduced the number of drinks per drinking days (7 studies, 451 participants, mean difference (MD) -1.13 drinks per drinking days, 95% Cl -1.79 to -0.46). After the exclusion of studies with high risk of bias, the number of abstinent remained higher (RR 1.69, 95% CI 1.18 to 2.43) and the number of drinks per drinking days lower (MD -1.21 number of drinks per drinking days, 95% CI -1.91 to -0.51) among participants who received antidepressants compared to those who received placebo. However, other outcomes such as the rate of abstinent days did not differ between antidepressants and placebo (9 studies, 821 participants, MD 1.34, 95% Cl -1.66 to 4.34; low-quality evidence).Low-quality evidence suggested no differences between antidepressants and placebo in the number of dropouts (17 studies, 1159 participants, RR 0.98, 95% Cl 0.79 to 1.22) and adverse events as withdrawal for medical reasons (10 studies, 947 participants, RR 1.15, 95% Cl 0.65 to 2.04).There were few studies comparing one antidepressant versus another antidepressant or antidepressants versus other interventions, and these had a small sample size and were heterogeneous in terms of the types of interventions that were compared, yielding results that were not informative.

Authors' conclusions: We found low-quality evidence supporting the clinical use of antidepressants in the treatment of people with co-occurring depression and alcohol dependence. Antidepressants had positive effects on certain relevant outcomes related to depression and alcohol use but not on other relevant outcomes. Moreover, most of these positive effects were no longer significant when studies with high risk of bias were excluded. Results were limited by the large number of studies showing high or unclear risk of bias and the low number of studies comparing one antidepressant to another or antidepressants to other medication. In people with co-occurring depression and alcohol dependence, the risk of developing adverse effects appeared to be minimal, especially for the newer classes of antidepressants (such as selective serotonin reuptake inhibitors). According to these results, in people with co-occurring depression and alcohol dependence, antidepressants may be useful for the treatment of depression, alcohol dependence, or both, although the clinical relevance may be modest.

PubMed Disclaimer

Conflict of interest statement

RA: no interests to declare relating to this work.

ET: no interests to declare relating to this work.

PP: no interests to declare relating to this work.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
4
4
Funnel plot of comparison: 1 Antidepressants versus placebo: all studies, outcome: 1.1 Depression severity: final score (interviewer‐rated scales).
5
5
Funnel plot of comparison: 1 Antidepressants versus placebo: all studies, outcome: 1.5 Response to antidepressive treatment.
6
6
Funnel plot of comparison: 1 Antidepressants versus placebo: all studies, outcome: 1.17 Acceptability: dropouts.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Adamson 2015 {published data only}
    1. Adamson SJ, Sellman JD, Foulds JA, Frampton CM, Deering D, Dunn A, et al. A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co‐occurring alcohol dependence and major depression. Journal of Clinical Psychopharmacology 2015;35(2):143‐9. - PubMed
    1. Foulds JA, Douglas Sellman J, Adamson SJ, Boden JM, Mulder RT, Joyce PR. Depression outcome in alcohol dependent patients: an evaluation of the role of independent and substance‐induced depression and other predictors. Journal of Affective Disorders 2015;174:503‐10. - PubMed
    1. Foulds JA, Ton K, Kennedy MA, Adamson SJ, Mulder RT, Sellman JD. OPRM1 genotype and naltrexone response in depressed alcohol‐dependent patients. Pharmacogenetics and Genomics 2015;25(5):270‐3. - PubMed
Altamura 1990 {published data only}
    1. Altamura AC, Mauri MC, Girardi T, Panetta B. Alcoholism and depression: a placebo controlled study with viloxazine. International Journal of Clinical Pharmacology Research 1990;10(5):293‐8. - PubMed
Altintoprak 2008 {published data only}
    1. Altintoprak AE, Zorlu N, Coskunol H, Akdeniz F, Kitapcioglu G. Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co‐morbid depressive disorder: a randomized, double‐blind study. Human Psychopharmacology 2008;23(4):313‐9. - PubMed
Butterworth 1971a {published data only}
    1. Butterworth AT, Watts RD. Treatment of hospitalized alcoholics with doxepin and diazepam. A controlled study. Quarterly Journal of Studies on Alcohol 1971;32(1):78‐81. - PubMed
Butterworth 1971b {published data only}
    1. Butterworth AT. Depression associated with alcohol withdrawal. Imipramine therapy compared with placebo. Quarterly Journal of Studies on Alcohol 1971;32(2):343‐8. - PubMed
Cocchi 1997 {published data only}
    1. Cocchi R. Paroxetine vs amitryptiline in depressed alcoholics. European Neuropsychopharmacology 1997;7(Suppl 2):S254.
Cornelius 1997 {published data only}
    1. Cornelius JC. Fluoxetine versus placebo in depressed alcoholics. Psychopharmacology. Psychopharmacology Bulletin 1994;30(4):661. - PubMed
    1. Cornelius JR, Salloum IM, Cornelius MD, Perel JM, Ehler JG, Jarrett PJ, et al. Preliminary report: double‐blind, placebo‐controlled study of fluoxetine in depressed alcoholics. Psychopharmacology Bulletin 1995;31(2):297‐303. - PubMed
    1. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Black A, et al. Double‐blind fluoxetine in depressed alcoholic smokers. Psychopharmacology Bulletin 1997;33(1):165‐70. - PubMed
    1. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Perel JM, et al. Fluoxetine in depressed alcoholics. A double‐blind, placebo‐controlled trial. Archives of General Psychiatry 1997;54(8):700‐5. - PubMed
    1. Cornelius JR, Salloum IM, Haskett RF, Daley DC, Cornelius MD, Thase ME, et al. Fluoxetine versus placebo in depressed alcoholics: a 1‐year follow‐up study. Addictive Behaviors 2000;25(2):307‐10. - PubMed
Cornelius 2016 {published data only}
    1. Cornelius J, Chung T, Douaihy A, Glance J. Mirtazapine pilot trial in youthful MDD/AUD subjects. American Journal on Addictions / American Academy of Psychiatrists in Alcoholism and Addictions 2017;26(3):250‐1.
    1. Cornelius J, Chung T, Douaihy A, Glance J, Kmiec J, Wesesky M, et al. Double‐blind mirtazapine pilot trial in AUD/MDD. Alcoholism, Clinical and Experimental Research 2016;40:233.
    1. Cornelius JR, Chung T, Douaihy AB, Kirisci L, Glance J, Kmiec J, et al. Mirtazapine in comorbid major depression and an alcohol use disorder: a double‐blind placebo‐controlled pilot trial. Psychiatry Research 2016;242:326‐30. [DOI: 10.1016/j.psychres.2016.06.005] - DOI - PMC - PubMed
    1. Cornelius JR, Chung TA, Wesesky MA, Douaihy A, Fitzgerald D, Kirisci L, et al. Combined young and older adult mirtazapine pilot trials in AUD/MDD. Alcoholism: Clinical and Experimental Research 2017;41:176A.
Gallant 1969 arm a {published data only}
    1. Gallant DM, Bishop MP, Guerrero‐Figueroa R, Selby M, Phillips R. Doxepin versus diazepam: a controlled evaluation in 100 chronic alcoholic patients. Journal of Clinical Pharmacology and New Drugs 1969;9(1):57‐65. - PubMed
Gallant 1969 arm b {published data only}
    1. Gallant DM, Bishop MP, Guerrero‐Figueroa R, Selby M, Phillips R. Doxepin versus diazepam: a controlled evaluation in 100 chronic alcoholic patients. Journal of Clinical Pharmacology and New Drugs 1969;9(1):57‐65. - PubMed
Gual 2003 {published data only}
    1. Gual A, Balcells M, Torres M, Madrigal M, Diez T, Serrano L. Sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder: a randomized controlled trial. Alcohol and Alcoholism (Oxford, Oxfordshire) 2003;38(6):619‐25. - PubMed
Habrat 2006 {published data only}
    1. Habrat B, Zaloga B. A double‐blind controlled study of the efficacy and acceptability of tianeptine in comparison with fluvoxamine in the treatment of depressed alcoholic patients. Psychiatria Polska 2006;40(3):579‐97. - PubMed
Hernandez‐Avila 2004 {published data only}
    1. Hernandez‐Avila CA, Modesto‐Lowe V, Feinn R, Kranzler HR. Nefazodone treatment of comorbid alcohol dependence and major depression. Alcoholism, Clinical and Experimental Research 2004;28(3):433‐40. - PubMed
Kranzler 2006 arm A {published data only}
    1. Kranzler HR, Mueller T, Cornelius J, Pettinati HM, Moak D, Martin PR, et al. Sertraline treatment of co‐occurring alcohol dependence and major depression. Journal of Clinical Psychopharmacology 2006;26(1):13‐20. - PubMed
Kranzler 2006 arm B {published data only}
    1. Kranzler HR, Mueller T, Cornelius J, Pettinati HM, Moak D, Martin PR, et al. Sertraline treatment of co‐occurring alcohol dependence and major depression. Journal of Clinical Psychopharmacology 2006;26(1):13‐20. - PubMed
Krupitsky 1993 arm A {published data only}
    1. Krupitsky EM, Burakov AM, Grinenko AIa, Borodkin IuS. Effect of pharmacotherapy of affective disorders on the psycho‐semantics of alcoholic patients. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 1995;95(6):67‐71. - PubMed
    1. Krupitsky EM, Burakov AM, Ivanov VB, Karandashova GF, Lapin IP, Grinenko Ala, et al. The use of baclofen for treating affective disorders in alcoholism. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 1994;94(1):57‐61. - PubMed
    1. Krupitsky EM, Burakov AM, Ivanov VB, Krandashova GF, Lapin IP, Grinenko AJa, et al. Baclofen administration for the treatment of affective disorders in alcoholic patients. Drug and Alcohol Dependence 1993;33(2):157‐63. - PubMed
Krupitsky 1993 arm B {published data only}
    1. Krupitsky EM, Burakov AM, Grinenko AIa, Borodkin IuS. Effect of pharmacotherapy of affective disorders on the psycho‐semantics of alcoholic patients. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 1995;95(6):67‐71. - PubMed
    1. Krupitsky EM, Burakov AM, Ivanov VB, Karandashova GF, Lapin IP, Grinenko AIa, et al. The use of baclofen for treating affective disorders in alcoholism. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 1994;94(1):57‐61. - PubMed
    1. Krupitsky EM, Burakov AM, Ivanov VB, Krandashova GF, Lapin IP, Grinenko AJa, et al. Baclofen administration for the treatment of affective disorders in alcoholic patients. Drug and Alcohol Dependence 1993;33(2):157‐63. - PubMed
Krupitsky 2012 {published data only}
    1. Krupitsky E, Yerish S, Kiselev A. Clinical trial of escitalopram for alcoholism comorbid with affective disorders. Alcoholism, Clinical and Experimental Research 2012;36:297A.
    1. Krupitsky E, Yerish S, Kiselev A. Clinical trial of escitalopram for alcoholism comorbid with affective disorders. European Neuropsychopharmacology 2010;20(Suppl 3):S571.
    1. Krupitsky EM, Yerish SM, Berntsev VA, Kiselev A, Alexandrovsky NA, Torban MN, et al. Double blind placebo controlled randomized clinical trial of escitalopram for alcoholism comorbid with affective disorders (depression and anxiety). ISBRA 2010 Poster Abstracts. 2010:167A.
    1. Krupitsky EM, Yerish SM, Kiselev AS, Berntsev VA, Alexandrovsky NA, Torban MN, et al. A double blind, placebo controlled, randomized clinical trial of escitalopram for the treatment of affective disorders in alcohol dependent patients in early remission. The International Psychiatry and Behavioral Neurosciences Yearbook. Boutros N. Vol. II, New York (NY): Nova Science Publishers, 2012:239‐56.
Liappas 2005 arm A {published data only}
    1. Liappas J, Paparrigopoulos T, Tzavellas E, Rabavilas A. Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification. Progress in Neuro‐psychopharmacology & Biological Psychiatry 2005;29(1):55‐60. - PubMed
Liappas 2005 arm B {published data only}
    1. Liappas J, Paparrigopoulos T, Tzavellas E, Rabavilas A. Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification. Progress in Neuro‐psychopharmacology & Biological Psychiatry 2005;29(1):55‐60. - PubMed
Liappas 2005 arm C {published data only}
    1. Liappas J, Paparrigopoulos T, Tzavellas E, Rabavilas A. Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification. Progress in Neuro‐psychopharmacology & Biological Psychiatry 2005;29(1):55‐60. - PubMed
Lôo 1988 {published data only}
    1. Lôo H, Malka R, Defrance R, Barrucand D, Benard JY, Niox‐Rivière H, et al. Tianeptine and amitriptyline. Controlled double‐blind trial in depressed alcoholic patients. Neuropsychobiology 1988;19(2):79‐85. - PubMed
Mason 1996 {published data only}
    1. Mason BJ, Kocsis JH. Desipramine treatment of alcoholism. Psychopharmacology Bulletin 1991;27(2):155‐61. - PubMed
    1. Mason BJ, Kocsis JH, Ritvo EC, Cutler RB. A double‐blind, placebo‐controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 1996;275(10):761‐7. - PubMed
McGrath 1996 {published data only}
    1. McGrath PJ, Nunes EV, Stewart JW, Goldman D, Agosti V, Ocepek‐Welikson K, et al. Imipramine treatment of alcoholics with primary depression: a placebo‐controlled clinical trial. Archives of General Psychiatry 1996;53(3):232‐40. - PubMed
    1. McGrath PJ, Nunes EV, Stewart JW, Ocepek‐Welikson K, Quitkin FM. Antidepressant treatment of primary depression in alcoholics: a placebo‐controlled randomized clinical trial. Psychopharmacology Bulletin. 1995:598.
McLean 1986 {published data only}
    1. McLean PC, Ancill RJ, Szulecka TK. Mianserin in the treatment of depressive symptoms in alcoholics. A double‐blind placebo controlled study using a computer delivered self‐rating scale. Psychiatria Polska 1986;20(6):417‐27. - PubMed
Moak 2003 {published data only}
    1. Moak DH, Anton RF, Latham PK, Voronin KE, Waid RL, Durazo‐Arvizu R. Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo‐controlled trial. Journal of Clinical Psychopharmacology 2003;23(6):553‐62. - PubMed
Muhonen 2008 {published data only}
    1. Muhonen LH, Lahti J, Alho H, Lönnqvist J, Haukka J, Saarikoski ST. Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence. Psychiatry Research 2011;186(1):53‐7. - PubMed
    1. Muhonen LH, Lahti J, Sinclair D, Lönnqvist J, Alho H. Treatment of alcohol dependence in patients with co‐morbid major depressive disorder ‐ predictors for the outcomes with memantine and escitalopram medication. Substance Abuse Treatment, Prevention, and Policy 2008;3:20. - PMC - PubMed
    1. Muhonen LH, Lönnqvist J, Juva K, Alho H. Double‐blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. Journal of Clinical Psychiatry 2008;69(3):392‐9. - PubMed
    1. Muhonen LH, Lönnqvist J, Lahti J, Alho H. Age at onset of first depressive episode as a predictor for escitalopram treatment of major depression comorbid with alcohol dependence. Psychiatry Research 2009;167(1‐2):115‐22. - PubMed
Nunes 1993 {published data only}
    1. Nunes EV, McGrath PJ, Quitkin FM, Stewart JP, Harrison W, Tricamo E, et al. Imipramine treatment of alcoholism with comorbid depression. American Journal of Psychiatry 1993;150(6):963‐5. - PubMed
Pettinati 2001a {published data only}
    1. Dundon W, Lynch KG, Pettinati HM, Lipkin C. Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy. Alcoholism, Clinical and Experimental Research 2004;28(7):1065‐73. - PMC - PubMed
    1. Levin SC. The efficacy of sertraline treatment for subtypes of alcohol dependence: advancing individualized treatments. Dissertation Abstracts International 2010;71(4‐B2):2333.
    1. Pettinati HM, Dundon W, Lipkin C. Gender differences in response to sertraline pharmacotherapy in Type A alcohol dependence. American Journal on Addictions / American Academy of Psychiatrists in Alcoholism and Addictions 2004;13(3):236‐47. - PubMed
    1. Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcoholism, Clinical and Experimental Research 2000;24(7):1041‐9. - PubMed
    1. Pettinati HM, Volpicelli JR, Luck G, Kranzler HR, Rukstalis MR, Cnaan A. Double‐blind clinical trial of sertraline treatment for alcohol dependence. Journal of Clinical Psychopharmacology 2001;21(2):143‐53. - PubMed
Pettinati 2010 arm A {published data only}
    1. NCT00004554. Sertraline for alcohol dependence and depression. clinicaltrials.gov/ct2/show/NCT00004554 Date first received: 7 February 2000.
    1. Pettinati HM, Leshner AR, Dundon WD. Sertraline treatment in subtypes of alcohol dependence: a replication. Alcoholism: Clinical and Experimental Research 2012;36:245A.
    1. Pettinati HM, Oslin DW, Kampman KM, Dundon WD, Xie H, Gallis TL, et al. A double‐blind, placebo‐controlled trial combining sertraline and naltrexone for treating co‐occurring depression and alcohol dependence. American Journal of Psychiatry 2010;167(6):668‐75. - PMC - PubMed
    1. Roth TL, Mahoney EM, Dundon WD, Pettinati HM. Combination pharmacotherapy sertraline and naltrexone decreases suicidal ideation scores in co‐morbid depressed alcoholics. Alcoholism: Clinical and Experimental Research 2012;36:245A.
Pettinati 2010 arm B {published data only}
    1. NCT00004554. Sertraline for alcohol dependence and depression. clinicaltrials.gov/ct2/show/NCT00004554 Date first received: 7 February 2000.
    1. Pettinati HM, Leshner AR, Dundon WD. Sertraline treatment in subtypes of alcohol dependence: a replication. Alcoholism: Clinical and Experimental Research 2012;36:245A.
    1. Pettinati HM, Oslin DW, Kampman KM, Dundon WD, Xie H, Gallis TL, et al. A double‐blind, placebo‐controlled trial combining sertraline and naltrexone for treating co‐occurring depression and alcohol dependence. American Journal of Psychiatry 210;167(6):668‐75. - PMC - PubMed
    1. Roth TL, Mahoney EM, Dundon WD, Pettinati HM. Combination pharmacotherapy sertraline and naltrexone decreases suicidal ideation scores in co‐morbid depressed alcoholics. Alcoholism: Clinical and Experimental Research 2012;36:245A.
Roy 1998 {published data only}
    1. Roy A. Placebo‐controlled study of sertraline in depressed recently abstinent alcoholics. Biological Psychiatry 1998;44(7):633‐7. - PubMed
    1. Roy A. Treatment of depressed alcoholics. 150th Annual Meeting of the American Psychiatric Association; 1997 May 17‐22; San Diego (CA). 1997:151.
Roy‐Byrne 2000 {published data only}
    1. Roy‐Byrne PP, Pages KP, Russo JE, Jaffe C, Blume AW, Kingsley E, et al. Nefazodone treatment of major depression in alcohol‐dependent patients: a double‐blind, placebo‐controlled trial. Journal of Clinical Psychopharmacology 2000;20(2):129‐36. - PubMed

References to studies excluded from this review

Anthenelli 2014 {published data only}
    1. Anthenelli RM, Blom TJ, Heffner JL, Higley AE, Bekman NM, Doran N, et al. Central serotonergic & peripheral mechanisms underlie sex‐sensitive, stressor‐specific endocrine responses in alcohol dependent subjects and controls. Alcoholism: Clinical and Experimental Research 2014;38:85A.
Arnow 2015 {published data only}
    1. Arnow BA, Blasey C, Williams LM, Palmer DM, Rekshan W, Schatzberg AF, et al. Depression subtypes in predicting antidepressant response: a report from the iSPOT‐D trial. American Journal of Psychiatry 2015;172(8):743‐50. - PubMed
Balaratnasingam 2011 {published data only}
    1. Balaratnasingam S, Janca A. Combining sertraline and naltrexone in the treatment of adults with comorbid depression and alcohol dependence. Current Psychiatry Reports 2011;13(4):245‐7. - PubMed
Bandati 2013 {published data only}
    1. Bandati A, Bandati AO, Albu A. Management of affective disorders in alcohol‐dependent patients. European Neuropsychopharmacology 2013;23:S564‐5.
Batki 2015 {published data only}
    1. Batki S, Pennington D, Meyerhoff D, Spigelman I, Back S, Petrakis I. Pharmacologic therapies for alcohol use disorder and PTSD. Alcoholism, Clinical and Experimental Research 2015;39:289A.
Bowman 1966 {published data only}
    1. Bowman EH, Thimann J. Treatment of alcoholism in the subacute stage. (A study of three active agents). Diseases of the Nervous System 1966;27(5):342‐6. - PubMed
Brewer 2015 {published data only}
    1. Brewer A, Thompson‐Lake DG, Mahoney JJ, Newton TF, Garza R. Evaluation of lisdexamfetamine alone and lisdexamfetamine + modafinil for cocaine use disorder. Drug and Alcohol Dependence 2015;146:e231.
Brown 2003 {published data only}
    1. Brown ES, Bobadilla L, Nejtek VA, Perantie D, Dhillon H, Frol A. Open‐label nefazodone in patients with a major depressive episode and alcohol dependence. Progress in Neuro‐psychopharmacology & Biological Psychiatry 2003;27(4):681‐5. - PubMed
Brunelin 2014 {published data only}
    1. Brunelin J, Jalenques I, Trojak B, Attal J, Szekely D, Gay A, et al. The efficacy and safety of low frequency repetitive transcranial magnetic stimulation for treatment‐resistant depression: the results from a large multicenter French RCT. Brain Stimulation 2014;7(6):855‐63. - PubMed
Charney 2015 {published data only}
    1. Charney DA, Heath LM, Zikos E, Palacios‐Boix J, Gill KJ. Poorer drinking outcomes with citalopram treatment for alcohol dependence: a randomized, double‐blind, placebo‐controlled trial. Alcoholism, Clinical and Experimental Research 2015;39(9):1756‐65. - PubMed
Charnoff 1967 {published data only}
    1. Charnoff SM. Long‐term treatment of alcoholism with amitriptyline and emylcamate. A double‐blind evaluation. Quarterly Journal of Studies on Alcohol 1967;28(2):289‐94. - PubMed
Chick 2004b {published data only}
    1. Chick J, Aschauer H, Hornik K, Investigators' Group. Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one‐year, double‐blind, placebo‐controlled multicentre study with analysis by typology. Drug and Alcohol Dependence 2004;74(1):61‐70. - PubMed
Clark 2003 {published data only}
    1. Clark DB, Wood DS, Cornelius JR, Bukstein OG, Martin CS. Clinical practices in the pharmacological treatment of comorbid psychopathology in adolescents with alcohol use disorders. Journal of Substance Abuse Treatment 2003;25(4):293‐5. - PubMed
Cornelius 1993 {published data only}
    1. Cornelius JR, Salloum IM, Cornelius MD, Perel JM, Thase ME, Ehler JG, et al. Fluoxetine trial in suicidal depressed alcoholics. Psychopharmacology Bulletin 1993;29(2):195‐9. - PubMed
Cornelius 2011 {published data only}
    1. Cornelius JR, Douaihy A, Bukstein OG, Daley DC, Wood SD, Kelly TM, et al. Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a treatment trial of comorbid MDD/AUD adolescents. Addictive Behaviors 2011;36(8):843‐8. - PMC - PubMed
Cornelius 2012 {published data only}
    1. Cornelius JR, Douaihy A, Clark DB. Mirtazapine pilot trial in depressed alcoholics. American Journal on Addictions / American Academy of Psychiatrists in Alcoholism and Addictions 2012;21(4):392.
    1. Cornelius JR, Douaihy AB, Clark DB, Chung T, Wood DS, Daley D. Mirtazapine in comorbid major depression and alcohol dependence: an open‐label trial. Journal of Dual Diagnosis 2012;8(3):200‐4. - PMC - PubMed
Davis 2005 {published data only}
    1. Davis LL, Rush JA, Wisniewski SR, Rice K, Cassano P, Jewell ME, et al. Substance use disorder comorbidity in major depressive disorder: an exploratory analysis of the Sequenced Treatment Alternatives to Relieve Depression cohort. Comprehensive Psychiatry 2005;46(2):81‐9. - PubMed
    1. Davis LL, Wisniewski SR, Howland RH, Trivedi MH, Husain MM, Fava M, et al. Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. Drugs and Alcohol Dependence 2010;107(2‐3):161‐70. - PubMed
Desai 1999 {published data only}
    1. Desai N, Losardo M, Farrell D, Penk W, Petrakis I, Rounsaville B. The efficacy of sertraline versus fluoxetine in Veterans comorbid depression and alcohol dependence. Abstract. 1999:45.
Douglas 1996 {published data only}
    1. Douglas MB, Fleming MF. Treating depression in alcoholics. Journal of Family Practice 1996;42(6):565‐6. - PubMed
Eriksson 2001 {published data only}
    1. Eriksson M, Berggren U, Blennow K, Fahlke C, Balldin J. Further investigation of citalopram on alcohol consumption in heavy drinkers: responsiveness possibly linked to the DRD2 A2/A2 genotype. Alcohol 2001;24(1):15‐23. - PubMed
Farren 1999 {published data only}
    1. Farren CK, O'Malley SS. Occurrence and management of depression in the context of naltrexone treatment of alcoholism. American Journal of Psychiatry 1999;156(8):1258‐62. - PubMed
Foulds 2016 {published data only}
    1. Foulds JA, Sellman JD, Mulder RT. Antidepressant therapy for depressed patients with an alcohol use disorder. Australian and New Zealand Journal of Psychiatry 2016;50(3):199‐200. - PubMed
García‐Portilla 2005 {published data only}
    1. García‐Portilla MP, Bascarán MT, Saiz PA, Mateos M, González‐Quirós M, Pérez P, et al. Effectiveness of venlafaxine in the treatment of alcohol dependence with comorbid depression. Actas Espanolas de Psiquiatria 2005;33(1):41‐5. - PubMed
Glasner‐Edwards 2007 {published data only}
    1. Glasner‐Edwards S, Tate SR, McQuaid JR, Cummins K, Granholm E, Brown SA. Mechanisms of action in integrated cognitive‐behavioral treatment versus twelve‐step facilitation for substance‐dependent adults with comorbid major depression. Journal of Studies on Alcohol and Drugs 2007;68(5):663‐72. - PubMed
Gorelick 1992 {published data only}
    1. Gorelick DA, Paredes A. Effect of fluoxetine on alcohol consumption in male alcoholics. Alcoholism, Clinical and Experimental Research 1992;16(2):261‐5. - PubMed
Grelotti 2014 {published data only}
    1. Grelotti DJ, Hammer GP, Dilley JW, Karasic DH, Sorensen JL, Bangsberg DR, et al. Does substance use compromise depression treatment? A randomized trial of homeless HIV+ persons. Topics in Antiviral Medicine 2014;22(e‐1):541‐2.
Han 2013 {published data only}
    1. Han DH, Kim SM, Choi JE, Min KJ, Renshaw PF. Adjunctive aripiprazole therapy with escitalopram in patients with co‐morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence. Journal of Psychopharmacology (Oxford, England) 2013;27(3):282‐91. - PMC - PubMed
Hautzinger 2005 {published data only}
    1. Hautzinger M, Wetzel H, Szegedi A, Scheurich A, Lörch B, Singer P, et al. Combination treatment with SSRI and cognitive behavior therapy for relapse prevention of alcohol‐dependent men. Results of a randomized, controlled multicenter therapeutic study. Nervenarzt 2005;76(3):295‐307. - PubMed
Ionescu 2011 {published data only}
    1. Ionescu D, Dehelean C, Funar TS, Dumache R. A comparative evaluation of therapy escitalopram versus memantine in the case of patients with alcohol dependence and co‐morbid major depressive disorder. Toxicology Letters 2011;205:S89.
Ivanets 1998 {published data only}
    1. Ivanets NN. Treatment of alcoholism with antidepressant mianserin. 5th World Congress on Innovations in Psychiatry; 1998 19‐22 May; London. 1998:S27.
    1. Ivanets NN, Anokhina IP, Kogan BM, Chirko VV, Nebarakova TP, Rusinov AV. The efficacy and mechanisms of action of lerivon in alcoholism. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 1996;96(5):52‐8. - PubMed
Janiri 1996 {published data only}
    1. Janiri L, Gobbi G, Mannelli P, Pozzi G, Serretti A, Tempesta E. Effects of fluoxetine at antidepressant doses on short‐term outcome of detoxified alcoholics. International Clinical Psychopharmacology 1996;11(2):109‐17. - PubMed
Janiri 1997 {published data only}
    1. Janiri L, Hadjichristos A, Lombardi U, Rago R, Mannelli P, Tempesta E. SSRIs in alcoholism: fluvoxamine vs fluoxetine in alcoholic outpatients. Sixth World Congress of Biological Psychiatry; 1997 Jun 22‐27; Nice. 1997:35S.
Kalyoncu 2007 {published data only}
    1. Kalyoncu OA, Mirsal H, Pektas O, Tan D, Beyazyurek M. The efficacy of venlafaxine on depressive symptoms of patients diagnosed with both alcohol use disorder and major depressive disorder. Journal of Dependence 2007;8(2):59‐65.
Kranzler 1995 {published data only}
    1. Kranzler HR, Burleson JA, Korner P, Boca FK, Bohn MJ, Brown J, et al. Placebo‐controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. American Journal of Psychiatry 1995;152(3):391‐7. - PubMed
Kranzler 2011 {published data only}
    1. Kranzler HR, Armeli S, Tennen H. Post‐treatment outcomes in a double‐blind, randomized trial of sertraline for alcohol dependence. Alcoholism, Clinical and Experimental Research 2012;36(4):739‐44. - PMC - PubMed
    1. Kranzler HR, Armeli S, Tennen H, Covault J, Feinn R, Arias AJ, et al. A double‐blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5‐hydroxytryptamine transporter‐linked promoter region genotype. Journal of Clinical Psychopharmacology 2011;31(1):22‐30. - PMC - PubMed
Krupitsky 2013 {published data only}
    1. Krupitsky EM, Yerish SM, Rybakova KV, Kiselev AS. Single blind placebo controlled randomized clinical trial of trazodon for alcoholism comorbid with affective disorders. Alcoholism, Clinical and Experimental Research 2013;37:18A.
Krystal 2008 {published data only}
    1. Krystal JH, Gueorguieva R, Cramer J, Collins J, Rosenheck R, VA CSP No. 425 Study Team. Naltrexone is associated with reduced drinking by alcohol dependent patients receiving antidepressants for mood and anxiety symptoms: results from VA Cooperative Study No. 425, "Naltrexone in the treatment of alcoholism". Alcoholism, Clinical and Experimental Research 2008;32(1):85‐91. - PubMed
Labbate 2004 {published data only}
    1. Labbate LA, Sonne SC, Randal CL, Anton RF, Brady KT. Does comorbid anxiety or depression affect clinical outcomes in patients with post‐traumatic stress disorder and alcohol use disorders?. Comprehensive Psychiatry 2004;45(4):304‐10. - PubMed
Lee 2012 {published data only}
    1. Lee Y, Han D, Kim S, Park D, Na C. Augmentation therapy of aripiprazole with escitalopram in patients with co‐occurrence of depression and alcohol dependence. European Neuropsychopharmacology 2012;22:S389.
Liappas 2004 {published data only}
    1. Liappas J, Paparrigopoulos T, Malitas P, Tzavellas E, Christodoulou G. Mirtazapine improves alcohol detoxification. Journal of Psychopharmacology 2004;18(1):88‐93. - PubMed
Macher 1991 {published data only}
    1. Macher JP, Minot R, Duval F, Luthringer R, Toussaint M, Schaltenbrand N. Neuro‐electrophysiologic studies in abstinent and depressed alcoholic patients treated with tianeptine. Presse Medicale 1991;20(37):1853‐7. - PubMed
Malka 1992 {published data only}
    1. Malka R, Loo H, Ganry H, Souche A, Marey C, Kamoun A. Long‐term administration of tianeptine in depressed patients after alcohol withdrawal. British Journal of Psychiatry 1992;15 Suppl:66‐71. - PubMed
Marey 1991 {published data only}
    1. Marey C, Ganry H, Delalleau B, Kamoun A. Therapeutic effects of tianeptine in patients with depression and anxiety disorders with or without associated alcoholism. Presse Medicale 1991;20(37):1828‐36. - PubMed
Mason 1999 {published data only}
    1. Mason BJ, Salvato FR, Cutler RB, Cooper TB, Suckow RF, Williams LD. Naltrexone augmentation of sertraline in depressed alcoholics. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington (DC). 1999.
    1. Mason BJ, Salvato FR, Williams LD, Cutler RB. Naltrexone and/or sertraline in outpatients with alcoholism and depression. 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31‐Nov 4; Paris. 1999.
Naranjo 1997 {published data only}
    1. Naranjo CA, Bremner KE, Bazoon M, Turksen IB. Using fuzzy logic to predict response to citalopram in alcohol dependence. Clinical Pharmacology and Therapeutics 1997;62(2):209‐24. - PubMed
Oslin 2005 {published data only}
    1. Gopalakrishnan R, Ross J, O'Brien C, Oslin D. Course of late‐life depression with alcoholism following combination therapy. Journal of Studies on Alcohol 2009;70(2):237‐41. - PMC - PubMed
    1. Oslin DW. Treatment of late‐life depression complicated by alcohol dependence. American Journal of Geriatric Psychiatry 2005;13(6):491‐500. - PMC - PubMed
Overall 1973 {published data only}
    1. Overall JE, Brown D, Williams JD, Neill LT. Drug treatment of anxiety and depression in detoxified alcoholic patients. Archives of General Psychiatry 1973;29(2):218‐25. - PubMed
Powell 1995 {published data only}
    1. Powell BJ, Campbell JL, Landon JF, Liskow BI, Thomas HM, Nickel EJ, et al. A double‐blind, placebo‐controlled study of nortriptyline and bromocriptine in male alcoholics subtyped by comorbid psychiatric disorders. Alcoholism, Clinical and Experimental Research 1995;19(2):462‐8. - PubMed
Ruiz‐Mellott 2005 {published data only}
    1. Ruiz‐Mellott K, Poland R, Wilkins J. 5‐HTTLPR, antidepressant response, and alcohol use disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, GA. 2005:28.
Saatcioglu 2005 {published data only}
    1. Saatcioglu O, Evren C, Erim R, Cakmak D. Venlafaxine treatment in alcohol dependants with comorbid depression. European Neuropsychopharmacology 2005;Suppl 3:S589.
Salloum 2011 {published data only}
    1. Salloum IM, Cornelius JR, Douaihy A, Kirisci L. Gender difference in alcohol treatment response in patients with comorbid alcoholism and depression. Alcoholism, Clinical and Experimental Research 2011;35:19A.
Salloum 2013 {published data only}
    1. Salloum IM, Cornelius JR, Douaihy A, Daley DC. Predicting medication adherence and treatment completion among depressed alcoholics. Alcoholism, Clinical and Experimental Research 2013;37:198A.
Schottenfeld 1989 {published data only}
    1. Schottenfeld RS, O'Malley SS, Smith L, Rounsaville BJ, Jaffe JH. Limitation and potential hazards of MAOI's for the treatment of depressive symptoms in abstinent alcoholics. American Journal of Drug and Alcohol Abuse 1989;15(3):339‐44. - PubMed
Shaw 1975 {published data only}
    1. Shaw JA, Donley P, Morgan DW, Robinson JA. Treatment of depression in alcoholics. American Journal of Psychiatry 1975;132(6):641‐4. - PubMed
Witte 2012 {published data only}
    1. Witte J, Bentley K, Evins AE, Clain AJ, Baer L, Pedrelli P, et al. A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder. Journal of Clinical Pharmacology 2012;32(6):787‐96. - PMC - PubMed

References to studies awaiting assessment

Petrakis 2013 {published data only}
    1. Petrakis I, Jane JS, O'Brien E, Keegan K, Ralevski E, Desai N. Effect of depression on outcomes in a clinical trial evaluating antidepressants +/‐ naltrexone for treatment of alcohol dependence and PTSD. Alcoholism, Clinical and Experimental Research 2013;37:19A.
    1. Petrakis IL, Ralevski E, Desai N, Trevisan L, Gueorguieva R, Rounsaville B, et al. Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. Neuropsychopharmacology 2012;37(4):996‐1004. - PMC - PubMed
Schifano 1993 {published data only}
    1. Schifano F, Garofoli F. Dothiepin vs. S‐adenosylmethionine (SAMe) for the treatment of major depression in weaned alcoholics: a pilot study. European Neuropsychopharmacology 1993;3(3):330.

Additional references

Anton 1996
    1. Anton RR, Moak DH, Latham PK. The obsessive compulsive drinking scale: a new method of assessing outcome in alcoholism treatment studies. Archives of General Psychiatry 1996;53:225‐31. - PubMed
APA 1980
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington (DC): American Psychiatric Association, 1980.
APA 1987
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM III‐R). Washington (DC): American Psychiatric Press, 1987.
APA 1994
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington (DC): American Psychiatric Press, 1994.
APA 2000
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM‐IV‐TR). Washington (DC): American Psychiatric Association, 2000.
APA 2013
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Arlington (VA): American Psychiatric Association, 2013.
Artigas 2002
    1. Artigas F, Nutt DJ, Shelton R. Mechanism of action of antidepressants. Psychopharmacology Bulletin 2002;36(Suppl 2):123‐32. - PubMed
Babor 1992
    1. Babor TF, Hofmann M, DelBoca FK, Hesselbrock V, Meyer RE, Dolinsky ZS, et al. Types of alcoholics, I. Evidence for an empirically derived typology based on indicators of vulnerability and severity. Archives of General Psychiatry 1992;49:599‐608. - PubMed
Beck 1961
    1. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961;4:561‐71. - PubMed
Beck 1988
    1. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. Journal of Consulting and Clinical Psychology 1988;56:893‐7. - PubMed
Beck 1996
    1. Beck AT, Steer RA, Brown GK. Beck Depression Inventory: Manual. 2nd Edition. San Antonio (TX): Harcourt Brace, 1996.
Brown 1995
    1. Brown SA, Inaba RK, Gillin JC, Schuckit MA, Stewart MA, Irwin MR. Alcoholism and affective disorder: clinical course of depressive symptoms. American Journal of Psychiatry 1995;152:45‐52. - PubMed
Busner 2009
    1. Busner J, Targum SD, Miller DS. The Clinical Global Impressions scale: errors in understanding and use. Comprehensive Psychiatry 2009;50(3):257‐62. - PubMed
Buysse 1989
    1. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Index: a new instrument for psychiatric practice and research. Psychiatry Research 1989;28:193‐213. - PubMed
Carboni 2004
    1. Carboni E, Silvagni A. Dopamine reuptake by norepinephrine neurons: exception or rule?. Critical Reviews in Neurobiology 2004;16(1‐2):121‐8. - PubMed
Carr 1981
    1. Carr AC, Ancill RJ, Ghosh A, Margo A. Direct assessment of depression by microcomputer. A feasibility study. Acta Psychiatrica Scandinavica 1981;64(5):415‐22. - PubMed
Chick 2004a
    1. Chick J, Aschauer H, Hornik K. Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one‐year, double blind, placebo‐controlled Multicentre study with analysis by typology. Drug and Alcohol Dependence 2004;74:61‐70. - PubMed
Cloninger 1988
    1. Cloninger CR, Sigvardsson S, Gilligan SB, Knorring AL, Reich T, Bohman M. Genetic heterogeneity and the classification of alcoholism. Advances in Alcohol and Substance Abuse 1988;7:3‐16. - PubMed
Derogatis 1974
    1. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist (HSCL): a self‐report symptom inventory. Behavioral Science 1974;19(1):1‐15. - PubMed
Edwards 1976
    1. Edwards G, Gross MM. Alcohol dependence: provisional description of a clinical syndrome. BMJ 1976;1(6017):1058‐61. - PMC - PubMed
Endicott 1976
    1. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scales: a procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry 1976;35:837‐44. - PubMed
Fillenbaum 1997
    1. Fillenbaum GG, Beekly D, Edland SD, Hughes JP, Heyman A, Belle G. Consortium to establish a registry for Alzheimer's disease: development, database structure, and selected findings. Topics in Health Information Management 1997;18(1):47‐58. - PubMed
First 1995
    1. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM‐IV Axis I Disorders, Patient Edition (SCID‐P), version 2. New York, New York State Psychiatric Institute, Biometrics Research 1995.
Flannery 1999
    1. Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn Alcohol Craving Scale. Alcoholism, Clinical and Experimental Research 1999;23(8):1289‐95. - PubMed
Foulds 2015
    1. Foulds JA, Adamson SJ, Boden JM, Williman JA, Mulder RT. Depression in patients with alcohol use disorders: systematic review and meta‐analysis of outcomes for independent and substance‐induced disorders. Journal of Affective Disorders 2015;185:47‐59. - PubMed
Goldman 1992
    1. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM‐IV: a review of measures of social functioning. American Journal of Psychiatry 1992;149(9):1148‐56. - PubMed
GRADE 2004
    1. The GRADE working group. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490‐4. - PMC - PubMed
Grant 1995
    1. Grant BF, Harford TC. Comorbidity between DSM‐IV alcohol use disorders and major depression: results of a national survey. Drug and Alcohol Dependence 1995;39:197‐206. - PubMed
Grant 2015
    1. Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. Epidemiology of DSM‐5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry 2015;72(8):757‐66. - PMC - PubMed
Guy 1975
    1. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville (MD): National Institute of Mental Health, 1975.
Guy 1976
    1. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington (DC): DHEW Publication, 1976.
Guyatt 2008
    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7560):924‐6. - PMC - PubMed
Guyatt 2011
    1. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence ‐ publication bias. Journal of Clinical Epidemiology 2011;64:1277‐82. - PubMed
Hamilton 1959
    1. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32:50‐5. - PubMed
Hamilton 1960
    1. Hamilton M. A rating scale for depression. Journal of Neurology and Psychiatry 1960;23:56‐61. - PMC - PubMed
Hamilton 1967
    1. Hamilton M. Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 1967;6:278‐96. - PubMed
Hamilton 1969
    1. Hamilton M. Diagnosis and rating of anxiety. British Journal of Psychiatry 1969;Special publication:76‐9.
Hasin 1996
    1. Hasin DS, Trautman KD, Miele GM, Samet S, Smith M, Endicott J. Psychiatric Research Interview for Substance and Mental disorders (PRISM): reliability for substance abusers. American Journal of Psychiatry 1996;153(9):1195‐201. - PubMed
Hasin 2005
    1. Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the national epidemiologic survey on alcoholism and related conditions. Archives of General Psychiatry 2005;62(10):1097‐106. - PubMed
Higgins 2011
    1. Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Iovieno 2011
    1. Iovieno N, Tedeschini E, Bentley KH, Evins AE, Papakostas GI. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta‐analysis of placebo‐controlled randomized trials. Journal of Clinical Psychiatry 2011;72(8):1144‐51. - PubMed
Kadden 1992
    1. Kadden R, Carroll K, Donovan D, Cooney N, Monti P. Cognitive‐behavioral coping skills therapy manual: a clinical research guide for therapists treating individuals with alcohol abuse and dependence. Vol. 3, Washington (DC): NIAAA Project MATCH Monograph Series, 1992.
Kranzler 1996
    1. Kranzler HR, Burleson JA, Brown J, Babor TF. Fluoxetine treatment seems to reduce the beneficial effects of cognitive behavioral therapy in type B alcoholics. Alcoholism, Clinical and Experimental Research 1996;20:1534‐41. - PubMed
Kranzler 2000
    1. Kranzler HR, Modesto‐Lowe V, Kirk J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo‐controlled trial. Neuropsychopharmacology 2000;22(5):493‐503. - PubMed
LeMoal 2007
    1. Moal M, Koob GF. Drug addiction: pathways to the disease and pathophysiological perspectives. European Neuropsychopharmacology 2007;17:377‐93. - PubMed
Levine 1986
    1. Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacology Bulletin 1986;22(2):343‐81. - PubMed
Lingjaerde 1987
    1. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. Acta Psychiatrica Scandinavica 1987;76(suppl 334):1‐96. - PubMed
McLellan 1992
    1. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The fifth edition of the Addiction Severity Index. Journal of Substance Abuse Treatment 1992;9(3):199‐213. - PubMed
Miller 1992
    1. Miller WR, Zweben A, DiClemente CC, Rychtarik RG. Motivational Enhancement Therapy Manual. Vol. 2, Washington (DC): Project MATCH Monograph Series. National Institute on Alcohol Abuse and Alcoholism, 1992.
Miller 1995
    1. Miller WR, Tonigan JS, Longabaugh R. The Drinker Inventory of Consequences (DrInC): an instrument for assessing adverse consequences of alcohol abuse (Project MATCH Monograph Series). NIH Publication No. 95‐3911. Vol. 4, Rockville (MD): US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, 1995.
Moher 2001
    1. Moher D, Jones A, Lepage L, CONSORT Group (Consolidated Standards for Reporting of Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomized trials. JAMA 2001;285:1992‐5. - PubMed
Montgomery 1979
    1. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382‐9. - PubMed
Naranjo 2001
    1. Naranjo CA, Knoke DM. The role of selective serotonin reuptake inhibitors in reducing alcohol consumption. Journal of Clinical Psychiatry 2001;62(Suppl 20):18‐25. - PubMed
Nunes 2004
    1. Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta‐analysis. JAMA 2004;29:1887‐96. - PubMed
Nunes 2006
    1. Nunes EV, Rounsaville BJ. Comorbidity of substance use with depression and other mental disorders: from Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM‐IV) to DSM‐V. Addiction 2006;101:S89‐96. - PubMed
O'Donnell 2011
    1. O'Donnell JM, Shelton RC. Drug Therapy of Depression and Anxiety Disorders. In: Brunton LL, Chabner BA, Knollmann BC editor(s). Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th Edition. Columbus (OH): McGraw‐Hill, Medical Publishing Division, 2011:397‐415.
Overall 1962
    1. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799‐812.
Pettinati 2000
    1. Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcoholism, Clinical and Experimental Research 2000;24(7):1041‐9. - PubMed
Pettinati 2001b
    1. Pettinati HM, Volpicelli JR, Luck G, Kranzler HR, Rukstalis MR, Cnaan A. Double‐blind clinical trial of sertraline treatment for alcohol dependence. Journal of Clinical Psychopharmacology 2001;21:143‐53. - PubMed
Pettinati 2004
    1. Pettinati HM. Antidepressant treatment of co‐occurring depression and alcohol dependence. Biological Psychiatry 2004;56:785‐92. - PubMed
Pettinati 2013
    1. Pettinati HM, O'Brien CP, Dundon WD. Current status of co‐occurring mood and substance use disorders: a new therapeutic target. American Journal of Psychiatry 2013;170(1):23‐30. - PMC - PubMed
Raistrick 1994
    1. Raistrick D, Bradshaw J, Tober G, Weiner J, Allison J, Healey C. Development of the Leeds Dependence Questionnaire (LDQ): a questionnaire to measure alcohol and opiate dependence in the context of a treatment evaluation package. Addiction 1994;89(5):563‐72. - PubMed
Regier 1990
    1. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith D, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 1990;264:2511‐8. - PubMed
Rockliff 1971
    1. Rockliff BW. A brief rating scale for antidepressant drug trials. Comprehensive Psychiatry 1971;12(2):122‐35. - PubMed
Saunders 1993
    1. Saunders JB, Aasland OG, Babor TF, Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption ‐ II. Addiction 1993;88(6):791‐804. - PubMed
Schneider 2009
    1. Schneider B. Substance use disorders and risk for completed suicide. Archives of Suicide Research 2009;13:303‐16. - PubMed
Schuckit 1997
    1. Schuckit MA, Tipp JE, Bergman M, Reich W, Hesselbrock VM, Smith TL. Comparison of induced and independent major depressive disorders in 2,945 alcoholics. American Journal of Psychiatry 1997;154:948‐57. - PubMed
Schuckit 2006
    1. Schuckit MA. Comorbidity between substance use disorders and psychiatric conditions. Addiction 2006;101(Suppl 1):76‐78. - PubMed
Schünemann 2006
    1. Schünemann HJ, Jaeschke R, Cook D, Bria W, El‐Solh A, Ernst A, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. American Journal of Respiratory and Critical Care Medicine 2006;174:605‐14. - PubMed
Scott 1976
    1. Scott J, Huskisson EC. Graphic representation of pain. Pain 1976;2:175‐84. - PubMed
Selzer 1971
    1. Selzer M. The Michigan Alcoholism Screening Test (MAST): the quest for a new diagnostic instrument. American Journal of Psychiatry 1971;127:1653‐8. - PubMed
Sheehan 1998
    1. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini‐International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM‐IV and ICD‐10. Journal of Clinical Psychiatry 1998;59(Suppl 20):22‐33. - PubMed
Shelton 1969
    1. Shelton J, Hollister LE, Gocka EF. The drinking behavior interview (an attempt to quantify alcoholic impairment). Diseases of the Nervous System 1969;30(7):464‐7. - PubMed
Sher 2005
    1. Sher L, Oquendo MA, Galfalvy HC, Grunebaum MF, Burke AK, Zalsman G, et al. The relationship of aggression to suicidal behavior in depressed patients with a history of alcoholism. Addictive behaviours 2005;30:1144‐53. - PubMed
Shirayama 2006
    1. Shirayama Y, Chaki S. Neurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodents. Current Neuropharmacology 2006;4(4):277‐91. - PMC - PubMed
Skinner 1982
    1. Skinner HA, Allen BA. Alcohol dependence syndrome: measurement and validation. Journal of Abnormal Psychology 1982;91:199‐209. - PubMed
Skinner 1984
    1. Skinner HA, Horn JL. Alcohol dependence scale: user's guide. Toronto: Addiction Research Foundation 1984.
Sobell 1992
    1. Sobell L, Sobell M. Timeline follow‐back: a technique for assessing self‐reported alcohol consumption. In: Litten RZ, Allen JP editor(s). Measuring Alcohol Consumption. Totowa (NJ): The Humana Press, 1992:41‐72.
Spielberger 1970
    1. Spielberger C, Gorsuch A, Lushene R. The State‐Trait Anxiety Inventory. Palo Alto (CA): Consulting Psychologists Press, 1970.
Spielberger 1983
    1. Spielberger CD, Gorsuch RL, Lushene RE, Vagg PR, Jacobs GA. State‐Trait Anxiety Inventory for Adults. Palo Alto (CA): Mind Garden, 1983.
Spitzer 1992
    1. Spitzer RL, Williams BW, Gibbon M, First MB. The Structured Clinical Interview for DSM‐III‐R (SCID). I: History, rationale, and description. Archives of General Psychiatry 1992;49:624‐9. - PubMed
Stahl 2003
    1. Stahl SM, Grady MM. Differences in mechanism of action between current and future antidepressants. Journal of Clinical Psychiatry 2003;64(Suppl 13):13‐7. - PubMed
Torrens 2005
    1. Torrens M, Fonseca F, Mateu G, Farré M. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta‐analysis. Drug and Alcohol Dependence 2005;78(1):1‐22. - PubMed
Ware 1992
    1. Ware JE, Sherbourne CD. The MOS 36‐item Short Form Health Survey I: conceptual framework and item selection. Medical Care 1992;30:473‐83. - PubMed
WHO 1993
    1. World Health Organization. The ICD 10. The ICD‐10 Classification of Mental and Behavioural Disorders. Diagnostic Criteria for Research. Geneva: WHO, 1993.
Wilcox 2004
    1. Wilcox HC, Conner KR, Caine ED. Association of alcohol and drug use disorders and completed suicide: an empirical review of cohort studies. Drug and Alcohol Dependence 2004;76S:11‐9. - PubMed
Zung 1965
    1. Zung WW. A self‐rating depression scale. Archives of General Psychiatry 1965;12:63‐70. - PubMed

References to other published versions of this review

Pani 2010
    1. Pani PP, Trogu E, Amato L, Davoli M. Antidepressants for the treatment of depression in alcohol dependent individuals. Cochrane Database of Systematic Reviews 2010, Issue 7. [DOI: 10.1002/14651858.CD008581] - DOI

Publication types

LinkOut - more resources